IDELALISIB
| Brand name | ZYDELIG |
|---|---|
| Active ingredient | IDELALISIB |
| Strength | 150MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2014 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9469643 | September 2033 | substance |
| 8865730 | March 2033 | substance, product |
| 10730879 | March 2033 | substance, product |
| 9492449 | March 2030 | use U-1914 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.